New data from Phase 3 studies showed superior SVR (viral cure) rates achieved with telaprevir-based combination therapy in people with hepatitis C, regardless of race or stage of liver disease
2010-11-02
(Press-News.org) Boston, MA, October 30, 2010 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments). Patients in the ADVANCE and ILLUMINATE studies were given telaprevir with pegylated-interferon and ribavirin for the first 12 weeks of the studies, followed by treatment with pegylated-interferon and ribavirin alone for a total of either 24 weeks or 48 weeks based on their response to treatment at weeks 4 and 12. Final data from the Phase 3 ADVANCE and ILLUMINATE studies are being presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which takes place in Boston October 29 to November 2.
"In our Phase 3 program, starting people with 12 weeks of telaprevir-based combination therapy resulted in significant improvements in viral cure rates, regardless of race, extent of liver damage or experience with prior treatment," said Robert Kauffman, M.D., Ph.D., Senior Vice President and Chief Medical Officer for Vertex. "The results of the ADVANCE and ILLUMINATE studies represent a major milestone in the development of telaprevir and offer hope for doctors and the millions of people living with hepatitis C who need new and more effective medicines."
Vertex Pharmaceuticals Incorporated is developing telaprevir in collaboration with Tibotec and Mitsubishi Tanabe Pharma.
Results from ADVANCE & ILLUMINATE
Overall in ADVANCE, 75% of people treated with a telaprevir-based combination regimen for 12 weeks, followed by an additional 12 or 36 weeks of pegylated-interferon and ribavirin alone, achieved SVR, compared to 44% of people treated with 48 weeks of pegylated-interferon and ribavirin alone. New data from this study showed that 62% of African Americans/Blacks achieved SVR with telaprevir compared to 25% of African Americans/Blacks who were treated with pegylated-interferon and ribavirin alone. Additionally, 62% of people with advanced liver fibrosis or cirrhosis (scarring of the liver) achieved SVR with telaprevir compared to 33% who were treated with pegylated-interferon and ribavirin alone.
Response-guided therapy was used in ADVANCE, whereby patients whose virus was undetectable at weeks 4 and 12 of treatment with telaprevir-based therapy were eligible to reduce their treatment time by half – from 48 weeks to 24 weeks. ILLUMINATE was designed to confirm both the use of response-guided therapy and to evaluate whether there was any benefit in extending therapy from 24 weeks to 48 weeks in people who met these criteria. In ADVANCE and ILLUMINATE, 58% and 65% of people, respectively, met these criteria for 24-week total treatment. In ILLUMINATE there was no benefit in extending therapy to 48 weeks.
In ILLUMINATE, 72% of people overall achieved SVR with telaprevir-based therapy. New data from this study showed that 60% of African Americans/Blacks and 63% of people with advanced liver fibrosis or cirrhosis achieved SVR with telaprevir-based therapy in the overall study analysis. Of African Americans/Blacks whose virus was undetectable at weeks 4 and 12, 88% of people achieved SVR in both the 24-week and 48-week randomized treatment arms. There was no control arm of pegylated-interferon and ribavirin alone in ILLUMINATE.
The safety and tolerability profile of telaprevir was consistent in both trials, with low discontinuation rates of all drugs during the telaprevir treatment phase due to adverse events.
"Less than half of people with the most common form of hepatitis C - genotype 1- achieve a viral cure with currently approved medicines, and factors such as race and extent of liver fibrosis can further limit cure rates to less than a third," said Ira Jacobson, M.D., Chief of the Division of Gastroenterology and Hepatology, at New York-Presbyterian Hospital/Weill Cornell Medical Center, and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College. "After treatment with telaprevir-based combination therapy in the ADVANCE study, 75% of people overall achieved a viral cure. Importantly, 62% of African Americans/Blacks and people with extensive liver disease achieved a viral cure – nearly twice as many as those who received pegylated-interferon and ribavirin alone."
ADVANCE
Treatment Group
RVR+
eRVR++
SVR
Overall
Percent of patients w/eRVR who achieved SVR
Bridging Fibrosis/Cirrhosis
African American/Black
Hispanic/
Latino
12-week
TVR- based- arm*
(n=363)
68%
(n=246/363)
58%
(n=212/363)
75%+/-
(n=271/363)
89%
(n=189/212)
62%
(n=45/73)
62%
(n=16/26)
74%
(n=26/35)
8-week TVR-based- arm**(n=364)
66%
(n=242/364)
57%
(n=207/364)
69%+/-
(n=250/364)
83%
(n=171/207)
53%
(n=45/85)
58%
(n=23/40)
66%
(n=29/44)
Control arm***(n=361)
9%
(n=34/361)
8%
(n=29/361)
44%
(n=158/361)
97%
(n=28/29)
33%
(n=24/73)
25%
(n=7/28)
39%
(n=15/38)
* 12 weeks of telaprevir (TVR), Pegasys(R) (PEG,
pegylated-interferon alfa-2a) and Copegus(R) (RBV,
ribavirin) followed by 12 or 36 weeks of only PEG and RBV, based
on response to treatment at week 4 and week 12
** 8 weeks of telaprevir (TVR) Pegasys (PEG, pegylated-interferon
alfa-2a) and Copegus (RBV, ribavirin) followed by 16 or 40 weeks
of only PEG and RBV, based on response to treatment at weeks 4 and
12
*** 48 weeks of PEG and RBV
+ RVR: rapid viral response; undetectable
( END
ELSE PRESS RELEASES FROM THIS DATE:
2010-11-02
A team of scientists has, for the first time, completely characterized an important chemical reaction that is critical to the formation of ground-level ozone in urban areas. The team's results indicate that computer models may be underestimating ozone levels in urban areas during episodes of poor air quality (smoggy days) by as much as five to 10 percent.
Ground level ozone poses significant health hazards to people, animals and plants; is the primary ingredient of smog; and gives polluted air its characteristic odor. It is known that even small increases in ozone concentrations ...
2010-11-02
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
AID is a B-lymphocyte enzyme that creates deliberate mutations in the DNA encoding antibodies, which helps produce an appropriate immune ...
2010-11-02
Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults. Through an assessment of clinical, tissue-based and molecular data for pediatric lung cancer, research published in the November edition of the Journal of Thoracic Oncology determined that pulmonary lesions found in ...
2010-11-02
Tracy Collier, an employee at Home Technologies in Newport News, Virginia, was walking her employer's Westie around the Center's manmade lake on Thursday when she saw a large, mysterious blob floating in the water.
Co-worker Charlie Schmuck says "The lake is behind our office. Tracy was walking by the lake, saw the object, and asked everyone else to come out and take a look."
Tracy thought it was "a huge dead snake."
Charlie thought it "looked like some weird underwater fungus, like the ones that explode when you poke them."
Perhaps because it was just a few days ...
2010-11-02
The Institute of Medicine (IOM) recently released a study, The Future of Nursing: Leading Change, Advancing Health. The report calls for new and expanded roles for nurses in a redesigned health care system. It recommends improving education for all nurses and allowing nurses to practice to the full extent of their license and ability. It advocates overhauling state scope of practice acts and suggests that advanced practice registered nurses (APRNs) -- certified registered nurse anesthetists, certified nurse-midwives, clinical nurse specialists, and certified nurse practitioners ...
2010-11-02
Boston – November 1, 2010 – The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
"As scientists are starting to connect genetics to brain function and behavior, we believe it is time ...
2010-11-02
CHAMPAIGN, Ill. — Money may not grow on trees, but energy could grow in grass. Researchers at the University of Illinois have completed the first extensive geographic yield and economic analysis of potential bioenergy grass crops in the Midwestern United States.
Demand for biofuels is increasing as Americans seek to expand renewable energy sources and mitigate the effects of fluctuating energy prices. Corn ethanol is the main biofuel on the market, but demand for ethanol competes with corn's availability as a food, and rising ethanol consumption could lead to higher food ...
2010-11-02
BOSTON (3:00 p.m. ET, November 1, 2010) — A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.
"PITs cause cells to self-destruct by interfering with the signaling pathways that regulate cell survival. As compounds that promote cell death, PITs show promise in halting ...
2010-11-02
Anger is an interesting emotion for psychologists. On the one hand, it's negative, but then it also has some of the features of positive emotions. For a new study published in Psychological Science, a journal of the Association for Psychological Science, researchers find that associating an object with anger actually makes people want the object—a kind of motivation that's normally associated with positive emotions.
People usually think of anger as a negative emotion. You're not supposed to get angry. But anger also has some positive features. For example, it activates ...
2010-11-02
Excess nitrogen from agricultural and urban lands is contaminating groundwater, streams, lakes and estuaries, where it causes harmful algal blooms and contributes to fish kills.
Cost-effective approaches to removing this nitrogen from croplands and urban stormwater runoff before it reaches sensitive water bodies have been elusive.
But simple and inexpensive technologies are on the horizon. A recent scientific workshop on denitrification brought together ecologists, engineers and policy experts to find answers.
Denitrification is a biological process carried out by ...
LAST 30 PRESS RELEASES:
[Press-News.org] New data from Phase 3 studies showed superior SVR (viral cure) rates achieved with telaprevir-based combination therapy in people with hepatitis C, regardless of race or stage of liver disease
